Lupus & antiphospholipid syndrome
Novel potential lncRNA biomarker in B cells indicates essential pathogenic pathway activation in patients with systemic lupus erythematosus (SLE)
Authors' conclusion
RP11-273G15.2 could act as a diagnostic and disease activity monitoring biomarker for SLE
Study context
- Population
- B cells of patients with SLE; independent cohort for RT-qPCR validation
- Comparison
- SLE B cells vs healthy controls and other autoimmune diseases
- Outcome
- lncRNA RP11-273G15.2 in SLE B cells
Methodological detailsWeighted gene coexpression network analysis (WGCNA), public bulk and single-cell RNA-sequencing data, independent validation cohort (RT-qPCR)
- WGCNA
- Public bulk and single-cell RNA-sequencing data
- Independent validation cohort (RT-qPCR)
Main finding
As reported in the abstract
Correlation of RP11-273G15.2 with interferon (IFN) scores
r=0.7329
p<0.0001
Correlation of RP11-273G15.2 with disease activity
r=0.4710
p=0.0005
Original publication
Novel potential lncRNA biomarker in B cells indicates essential pathogenic pathway activation in patients with SLE. Lupus Sci Med. Published 10 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →